Disease relevance of SCH34343

• Generally, CGP 31608 was less active than imipenem, Sch 34343, and the cephalosporins, except against Pseudomonas aeruginosa [1].
• In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria [2].
• In vitro activity of Sch 34343 against enterococci and other gram-positive bacteria [3].
• All organisms except a single strain of Fusobacterium necrogenes were inhibited by an 8 micrograms/ml concentration of either Sch 34343 or imipenem [2].
• Sch 34343 had a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria but was inactive against Pseudomonas aeruginosa and Pseudomonas maltophilia [4].

High impact information on SCH34343

• Imipenem and Sch 34343 were not affected; an additional three- to fivefold increase in the MIC's of these antibiotics (with the exception of piperacillin, imipenem, Sch 34343), seen with 218 R2, was associated with decreased permeability [5].
• The pharmacokinetics of Sch 34343, a new broad-spectrum penem antibiotic, was studied in subjects receiving 1 g of 14C-labeled drug by intravenous administration [6].
• Ninety percent of methicillin-susceptible Staphylococcus aureus and penicillin-susceptible streptococcal isolates were inhibited by Sch 34343 at concentrations of less than or equal to 0.125 micrograms/ml [3].
• The serum protein binding of Sch 34343 was ca. 65% [3].
• Sch 34343 was quite stable to hydrolysis by beta-lactamases, including both penicillinases and cephalosporinases [4].

Chemical compound and disease context of SCH34343

• Sch 34343 inhibited 50% of the 105 bacterial strains tested at concentrations ranging from less than 1.25 to 5.0 mg/l and 90% at 5.0 to 10.0 mg/l. Against Escherichia coli and Klebsiella pneumoniae strains with cefotaxime MICs greater than 5.0 mg/l, 1.0-4.0 mg/l of Sch 34343 was required for inhibition [7].
• The in-vitro activity (as measured by geometric mean MICs, mg/l) of Sch 34343 against aerobic and anaerobic bacteria was compared with that of 14 other selected beta-lactam antibiotics including aztreonam, latamoxef (moxalactam), ceftazidime and imipenem [8].

Biological context of SCH34343

• Sch 34343 was not hydrolysed by plasmid- or chromosomally-mediated beta-lactamases, was an excellent inhibitor of Richmond-Sykes type Ia beta-lactamases, and also inhibited, although less effectively, the common plasmid beta-lactamases [9].

Associations of SCH34343 with other chemical compounds

• The in-vitro activity of Sch 34343 was compared with that of penicillin and cefotaxime against clinical isolates of streptococci [10].
• Peak serum levels, AUCs, beta-phase half-life and recovery of Sch 34343 from the urine of mice indicated that it was similar to cephalothin and cefamandole [11].
• The penems, Sch 29482 and Sch 34343, were most active with all minimum inhibitory concentrations (MICs) at less than or equal to 4.0 micrograms/ml and MIC90s of less than or equal to 0.25 micrograms/ml [12].

Gene context of SCH34343

• Tests for the beta-lactamase susceptibility of Sch 34343 showed that only one PSE-3, one PSE-4 and one chromosomal beta-lactamase from a strain of Enterobacter cloacae were slightly active [13].
• In-vitro evaluation of Sch 34343: antimicrobial activity, beta-lactamase stability and inhibition [14].

Analytical, diagnostic and therapeutic context of SCH34343

• At the end of a 30-min intravenous infusion, the mean maximum concentration of drug in serum was 39 micrograms/ml for unchanged Sch 34343 and 49 mu eq/ml for total radioactivity [6].
• Using an agar dilution technique we examined the in-vitro activity of Sch 34343 against 485 clinical bacterial isolates [15].

References